Proscia: Emerging Biotechs, Small & Mid-Size CROs: We Now Have a Concentriq LS Package for You

The latest from the Proscia blog

Emerging biotechs, along with their small and mid-sized CRO counterparts, are establishing themselves as key players advancing the next generation of therapies. So, in line with our mission to rewire pathology for precision medicine, we’re fully empowering them with our Concentriq LS platform.

Trusted by 16 of the top 20 pharmaceutical companies, Concentriq LS provides a central, scalable hub for AI-driven workflows spanning discovery to diagnostics. And now, with right-sized packaging and pricing designed for smaller teams, the same proven platform is more accessible than ever—meeting you where you are today and growing with you as your science advances.

Purpose-Built For Today’s Needs

Emerging biotechs face unique pressures: small teams managing high-stakes decisions, ambitious pipelines running on tight timelines, and the need to do more with less. Concentriq LS meets these realities head-on so that you can:

• Get up-and-running quickly. The platform’s SaaS architecture streamlines deployments.
• Maximize resources by unifying your teams, applications, and data in a single environment.
• Rapidly realize time-to-value with an intuitive interface that puts features where you’d expect them.
• Seamlessly collaborate among stakeholders across departments, teams, and partners
• Centralize all of your pathology AI with access to our precision medicine portfolio of 120+ research and diagnostic applications and embedded foundation models at your fingertips.
• Focus on your work, not IT infrastructure. Concentriq is designed to leverage AWS’s industry-leading security, scalability, and performance.

Tate York, Director of Digital Microscopy and Image Analysis at NSA Labs summarized it best.

“Concentriq LS has been a huge benefit to the NSA Labs and our clients—having everything on a centralized platform for sharing images, storage, and management. The collaboration benefit alone is really, really great.”

Your Foundation for Tomorrow

Concentriq LS is more than a platform for your immediate needs. It’s a long-term foundation designed to grow with you, supporting future studies and expanding data volumes, teams, and technology ecosystems.

One Platform that Powers the Entire R&D Lifecycle

Therapeutic R&D is inherently additive, each stage building upon the last. But when data, teams, and tools are spread across disconnected systems, momentum stalls and insights get lost.

As a unified platform for discovery to diagnostics, Concentriq LS enables you to:

• Eliminate the need to implement and maintain separate systems for each phase of R&D.
• Unlock deeper insights informed by a unified view of your data and upstream results.
• Work faster towards milestones, saving substantial time and millions of dollars.

Scale Your Digital Footprint When You’re Ready

As your image repositories grow and your technology ecosystem expands, here’s how Conentriq LS keeps up.

• Enterprise scalability with elastic storage accommodates and stores as many images as you need while ensuring speed, performance, and cost-efficiency.
• World-class interoperability, enabled by an open API and support for industry standards, ensures that Concentriq LS seamlessly integrates with the scanners, LIMS, and AI applications you need–today and tomorrow.
• Support for unlimited users with comprehensive roles and permissions means that all of your stakeholders can have the right level of access.

Gain More than a Platform through Our Diagnostic Network

As an added benefit of working with Proscia, you’ll also gain access to our diagnostic network. These digital laboratories are partnering with biotech and biopharmaceutical companies in many ways:

• Providing real-world data to fuel studies and AI development. Our diagnostic network collectively has 12M+ whole slide images enhanced with molecular tests, pathology reports, and genomic profiles across 2M unique patients, available for licensing through our real-world data offering.
• Generating real-world evidence to support regulatory approval.
• Expanding distribution for companion diagnostics and image-based assays since they are already running digital practices.

As you advance your science and move closer to market, your platform should never be a limitation. If you’re ready to unify your pathology operations and accelerate R&D, let’s start a conversation about how Concentriq LS could be the last enterprise pathology platform you’ll ever need.

SOURCE: Proscia